Abstract
The amyloid cascade hypothesis of Alzheimer’s disease is an intriguing and complex pathway which alludes to the accumulation of amyloid (Aβ) aggregates as a key toxic event. In this regard, computational tools can be effectively used to study and design amyloid aggregation inhibitors and modulators. A number of in silico methods have been described in the literature, which use full-length Aβ proteins. However, these methods are computationally expensive. Herein, we describe an in silico method that uses the Aβ hexapeptide-derived steric-zipper octamer assembly as an alternative and effective model to predict the binding interactions of planar small molecule libraries with complex Aβ structures including oligomers, protofibrils, and fibrils. The method provides detailed steps involved in conducting molecular docking, the interpretation of results obtained including ligand-Aβ hexapeptide interactions, calculation of ligand binding energies, and its correlation with the ligand binding affinity. This octamer steric-zipper model represents a relevant prototype to explore and study the mechanisms of Aβ aggregation using small molecules.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8:499–509
Maji SK, Wang L, Greenwald J, Riek R (2009) Structure-activity relationship of amyloid fibrils. FEBS Lett 583:2610–2617
Murphy MP, LeVine H (2010) Alzheimer’s disease and the β-amyloid peptide. J Alzheimers Dis 19:311–323
Masters CL, Selkoe DJ (2012) Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer’s disease. Cold Spring Harb Perspect Med 2:a006262
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608
Kevin WT, Oosten-Hawle PV, Hewitt EW, Radford SE (2015) Amyloid fibres: inert end-stage aggregates or key players in disease? Trends Biochem Sci 40:719–727
Ries HM, Nussbaum-Krammer C (2016) Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases. Essays Biochem 60:181–190
Hamley IW (2012) The amyloid beta peptide. Chem Rev 112:5147–5192
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Master CL (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12:357–367
Belluti F, Rampa A, Gobbi S, Bisi A (2013) Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer’s disease: a patent review (2010 –2012). Expert Opin Ther Pat 23:581–596
Bu XL, Rao PPN, Wang YJ (2016) Anti-amyloid aggregation activity of natural compounds: implications for Alzheimer’s drug discovery. Mol Neurobiol 53:3565–3575
Bruggink KA, Muller M, Kuiperij HB, Verbeek MM (2012) Methods for analysis of amyloid-β aggregates. J Alzheimers Dis 28:735–758
Mohamed T, Shakeri A, Rao PPN (2016) Amyloid cascade in Alzheimer’s disease: recent advances in medicinal chemistry. Eur J Med Chem 113:258–272
Nguyen P, Derreumaux P (2014) Understanding amyloid fibril nucleation and Aβ oligomer/drug interactions from computer simulations. Acc Chem Res 47:603–611
Jiang L, Liu C, Leibly D, Landau M, Zhao M, Hughes MP, Eisenberg DS (2013) Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. elife 2:e00857
Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, Glabe CG (2007) Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization. Biochemistry 46:8850–8860
Bieschke J, Herbst M, Wiglenda T, Friederich RP, Boeddrich A, Schiele F, Kleckers D, Lopez del Amo JM, Gruning BA, Wang Q, Schmidt MR, Lurz R, Anwyl R, Schnoegl S, Fandrich M, Frank RF, Reif B, Gunther S, Walsh DM, Wanker EE (2011) Small-molecule conversion of toxic oligomers to nontoxic sheet-rich amyloid fibrils. Nat Chem Biol 8:93–101
Landau M, Sawaya MR, Faull KF, Laganowsky A, Jiang L, Sievers SA, Liu J, Barrio JR, Eisenberg D (2011) Towards a pharmacophore for amyloid. PLoS Biol 9:e1001080
Schirmer RH, Adler H, Pickhardt M, Mandelkow E (2011) Lest we forget you—methylene blue. Neurobiol Aging 32:2325.e7–2325.16
Petzer A, Harvey BH, Wegener G, Petzer JP (2012) Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol 258:403–409
Wu G, Roberson DH, Brooks CL III, Vieth M (2003) Detailed analysis of grid-based molecular docking: a case study of CDOCKER- A CHARMm-based MD docking algorithm. J Comput Chem 24:1549–1562
Colletier JP, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, Flot D, Cascio D, Sawaya MR, Eisenberg D (2011) Molecular basis for amyloid-β polymorphism. Proc Natl Acad Sci U S A 108:16938–16943
Petkova A, Yau W, Tycko R (2006) Experimental constraints on the quaternary structure in Alzheimer’s beta-amyloid fibrils. Biochemistry 45:498–512
Walti MA, Ravotti F, Arai H, Glabe CG, Wall JS, Bockmann A, Guntert P, Meier BH, Riek R (2016) Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril. Proc Natl Acad Sci U S A 113:E4976–E4984
Colvin MT, Silvers R, Frohm B, Su Y, Linse S, Griffin RG (2015) High resolution structural characterization of Aβ42 amyloid fibrils by magic angle spinning NMR. J Am Chem Soc 137:7509–7518
Rao PPN, Mohamed T, Teckwani K, Tin G (2015) Curcumin binding to beta amyloid: a computational study. Chem Biol Drug Des 86:813–820
Lopez de la Paz M, Serrano L (2004) Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci U S A 101:87–92
Pastor MT, Esteras-Chopo A, Serrano L (2007) Hacking the code of amyloid formation. Prion 1:9–14
Acknowledgments
The PPNR would like to thank the University of Waterloo, NSERC-Discovery RGPIN 03830-2014, and Ministry of Research and Innovation, Government of Ontario, Canada, for an Early Researcher Award (ERA) for the financial support. DD also thanks the National Institutes of Health (R15GM116006) for the financial support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Rao, P.P.N., Du, D. (2018). In Silico Strategies to Design Small Molecules to Study Beta-Amyloid Aggregation. In: Roy, K. (eds) Computational Modeling of Drugs Against Alzheimer’s Disease. Neuromethods, vol 132. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7404-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7404-7_10
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7403-0
Online ISBN: 978-1-4939-7404-7
eBook Packages: Springer Protocols